Literature DB >> 1329978

Activation of the oxygen-radical-generating system in granules of intact human neutrophils by a calcium ionophore (ionomycin).

C Dahlgren1, A Johansson, H Lundqvist, O W Bjerrum, N Borregaard.   

Abstract

Subcellular fractionation studies were performed on human neutrophils stimulated with ionomycin (a Ca(2+)-specific ionophore). The results of these studies revealed NADPH-oxidase activity, without any additive, both in the plasma membrane and in the specific granule fractions. After comparing these results with the NADPH oxidase activity induced by the ionophore in intact neutrophils, in differentiated HL-60 cells and in neutrophil cytoplasts, we conclude that ionomycin preferentially activates the NADPH oxidase pool located in the membrane of specific granules. Furthermore, we suggest that incorporation of granule membrane into the plasma membrane makes the associated NADPH oxidase less sensitive to activation induced by a rise in [Ca(2+)]i.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329978     DOI: 10.1016/0167-4889(92)90200-u

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  A rise in ionized calcium activates the neutrophil NADPH-oxidase but is not sufficient to directly translocate cytosolic p47phox or p67phox to b cytochrome containing membranes.

Authors:  C Movitz; C Sjölin; C Dahlgren
Journal:  Inflammation       Date:  1997-10       Impact factor: 4.092

2.  Lipopolysaccharide-induced gelatinase granule mobilization primes neutrophils for activation by galectin-3 and formylmethionyl-Leu-Phe.

Authors:  J Almkvist; J Fäldt; C Dahlgren; H Leffler; A Karlsson
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

3.  Activation of human neutrophils by mycobacterial phenolic glycolipids.

Authors:  J Fäldt; C Dahlgren; A Karlsson; A M Ahmed; D E Minnikin; M Ridell
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

4.  The serine protease inhibitor diisopropylfluorophosphate inhibits neutrophil NADPH-oxidase activity induced by the calcium ionophore ionomycin and serum opsonised yeast particles.

Authors:  H Lundqvist; C Dahlgren
Journal:  Inflamm Res       Date:  1995-12       Impact factor: 4.575

5.  Lipopolysaccharide-induced granule mobilization and priming of the neutrophil response to Helicobacter pylori peptide Hp(2-20), which activates formyl peptide receptor-like 1.

Authors:  Johan Bylund; Anna Karlsson; Francois Boulay; Claes Dahlgren
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

6.  Calcium mobilization and Rac1 activation are required for VCAM-1 (vascular cell adhesion molecule-1) stimulation of NADPH oxidase activity.

Authors:  Joan M Cook-Mills; Jacob D Johnson; Tracy L Deem; Atsuo Ochi; Lei Wang; Yi Zheng
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

7.  Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).

Authors:  Boris K Pliyev
Journal:  Mol Cell Biochem       Date:  2008-10-02       Impact factor: 3.396

8.  Serum protects against azurophil granule dependent down-regulation of complement receptor type 1 (CR1) on human neutrophils.

Authors:  J Lundahl; C Dahlgren; K Gustavsson; J Hed
Journal:  Inflamm Res       Date:  1995-10       Impact factor: 4.575

9.  Sirt3 deficiency does not affect venous thrombosis or NETosis despite mild elevation of intracellular ROS in platelets and neutrophils in mice.

Authors:  Hideki Hayashi; Deya Cherpokova; Kimberly Martinod; Thilo Witsch; Siu Ling Wong; Maureen Gallant; Stephen M Cifuni; Leonard P Guarente; Denisa D Wagner
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

10.  Functional characteristics of circulating granulocytes in severe congenital neutropenia caused by ELANE mutations.

Authors:  Qiao Liu; Martina Sundqvist; Wenyan Li; André Holdfeldt; Liang Zhang; Lena Björkman; Johan Bylund; Claes Dahlgren; Cai Wang; Xiaodong Zhao; Huamei Forsman
Journal:  BMC Pediatr       Date:  2019-06-08       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.